Biology and therapeutic advances for pediatric osteosarcoma

Neyssa Marina, Mark Gebhardt, Lisa Teot, Richard Gorlick

Research output: Contribution to journalReview article

523 Scopus citations


Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agent chemotherapy dramatically improved the outcome for these patients and the majority of modern series report 3-year disease-free survival of 60%-70%. This paper describes current strategies for treating patients with osteosarcoma as well as review of the clinical features, radiologic and diagnostic work-up, and pathology. The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development. Therapy-related sequelae and future directions in the biology and therapy for these patients are also discussed.

Original languageEnglish (US)
Pages (from-to)422-441
Number of pages20
Issue number4
StatePublished - Aug 13 2004


  • Biology
  • Multidisciplinary treatment
  • Pediatric osteosarcoma
  • Therapeutic advances
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Biology and therapeutic advances for pediatric osteosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9(4), 422-441.